Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DAWN
DAWN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DAWN News
AIGH Capital Fully Exits Lumen Technologies Stake
Feb 03 2026
Fool
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
Jan 21 2026
Benzinga
Day One Biopharmaceuticals Reports $155.4M Revenue for 2025, Projects 53% Growth in 2026
Jan 14 2026
seekingalpha
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
Jan 12 2026
Benzinga
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
Jan 12 2026
Benzinga
Day One Biopharmaceuticals Reports $155.4M OJEMDA Revenue for 2025
Jan 12 2026
NASDAQ.COM
Day One Biopharmaceuticals Reports $155.4M in 2025 Net Revenue, Up 172%
Jan 11 2026
Globenewswire
Day One Biopharmaceuticals Reports $155.4M in 2025 Net Revenue, Up 172%
Jan 11 2026
Yahoo Finance
Day One Acquires Mersana for $25 per Share, Expanding Oncology Pipeline
Jan 06 2026
Globenewswire
After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience
Dec 22 2025
NASDAQ.COM
Significant Options Trading on Friday: DAWN, XPO, UUUU
Dec 19 2025
NASDAQ.COM
FuelCell Energy Reports Impressive Q4 Performance, Alongside Trump Media & Technology, Micron Technology, Lululemon, and Other Major Stocks Rising on Thursday
Dec 18 2025
Benzinga
Day One Biopharma (DAWN) Reports Encouraging 3-Year Follow-Up Findings from Key Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
Dec 16 2025
Yahoo Finance
Mersana to be Acquired by Day One for Up to $55.25 per Share Amid Investigation
Dec 10 2025
Globenewswire
Needham Affirms Buy Rating for Day One Biopharmaceutical, Keeps $16 Price Target Intact
Nov 24 2025
Benzinga
Day One Biopharma Enhances Oncology Portfolio Through $285 Million Acquisition of Mersana
Nov 13 2025
Benzinga
Show More News
